Life Sciences

10 May 2018  |  North America  |  Market Research

Global Tissue Diagnostics Market, Forecast to 2022

Liquid Biopsy for Therapy Monitoring and Reimbursement Cuts Impede Long-term Prospects of Tissue Diagnostics Market

Infographics

×

Key Issues Addressed

Tissue diagnostic techniques are used to recognize specific antigens in preserved tissues. The process includes slicing thin tissue samples that are treated with a hematoxylin and eosin (H&E) stain, and then are formalin-fixed paraffin-embedded (FFPE) to diagnose tumors and other histopathology specimens. This has traditionally required skilled pat...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in July 2017 that centered around the state of their laboratories in 2017 and their expectations for 2018. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-over...

06 Feb 2018  |  Global  |  Mega Trends

Growth Opportunities in Clinical Trial Data Management and eClinical Solutions Market, Forecast to 2020

Digitization Presents Opportunities for Unified Cloud-based Platform Solutions to Optimize Clinical Trial Workflows

Infographics

×

Key Issues Addressed

The global clinical trial IT market is expected to grow from $2.63 billion in 2016 to $4.29 billion in 2020 at a compound annual growth rate (CAGR) of more than 13.0%. North America will continue to hold the largest market share (by revenue) in 2017, followed by Europe. Increasing clinical trial activities in the emerging Asia-Pacific markets and r...

10 Jan 2018  |  Asia Pacific  |  Mega Trends

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Ko...

21 Dec 2016  |  Africa  |  Market Research

African Pharmaceuticals Market, Forecast to 2020

Assessing Market Potential with a Focus on Kenya and Nigeria

Infographics

×

The pharmaceuticals market in Africa is expected to reach a business opportunity of $45 billion in 2020, propelled by a convergence of changing economic profiles, rapid urbanisation, increased healthcare spending and investment, and increasing incidence of chronic lifestyle diseases. The tropical climate of Africa makes the continent the largest re...

Readers of Lab Manager Magazine were invited to participate in an online survey in July 2016. To qualify for survey participation, readers had to play a role in their laboratory’s purchasing process, be familiar with their laboratory’s product budgets, and represent a laboratory that either uses or plans to use products in 1 or more of the 7 sp...

Given the ever-increasing cost of care, healthcare delivery is moving towards decentralisation. Service delivery from health settings such as mobile clinics, rapid retail clinics, and home settings demands the use of new-age clinic laboratory diagnostics. Effective delivery of healthcare services has created a business and technology convergence be...

The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...